The US Food and Drug Administration (FDA) has approved the first vaccine for respiratory syncytial virus (RSV) in the United States, the agency announced May 3. Arexvy, manufactured by GSK, is the world's first RSVvaccine for adults aged 60 years and older, the company said in an ...
A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or needing intensive care unit support for severe complicati
Moderna announced positive results Tuesday from its phase 3 trial of anRSV vaccine for older adults, revealing plans to submit the vaccine for regulatory approval, which includes review by the US Food and Drug Administration, in the first half of 2023. There's no approved vaccine for RSV, or...
April 6, 2023 / 5:36 PM EDT / CBS Boston BOSTON - A new RSV vaccine shows promise in preventing severe respiratory illness in seniors and infants. RSV is a virus that not only causes serious respiratory infection in infants, but in older adults as well. A new stu...
Grannis and colleagues used a test-negative study designed to compare the effectiveness of the RSV vaccine in adults aged 60 years or older admitted to a hospital or who had an ED visit for an RSV-like illness between Oct. 1, 2023, and March 31, 2024. The analysi...
Reference CDC. CDC recommends RSV vaccine for older adults. Published June 30, 2023. Accessed June 30, 2023.https://www.cdc.gov/media/releases/2023/s0629-rsv.html
2023年2月,《新英格兰医学杂志》(NEJM)发表了题为:Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults 的临床研究论文。 这项在60岁及以上的个体中进行单剂量注射的RSV疫苗的安全性和有效性评估3期临床试验中。12467名参与者接受了RSV疫苗Arexvy的接种,12499名参与者接受了安慰剂。结果显示,...
In September 2023, the MHLW approved GSK's RSV vaccine for the prevention of RSV (respiratory syncytial virus) disease for adults aged 60 years and above in Japan. The use of this vaccine should be in accordance with official recommendations. As with any vaccine, a protective immune response ...
In June and August 2023, effective vaccines against RSV were approved for the first time by the European Medicines Agency (EMA) for the EU. The respective pivotal studies showed a very high efficacy of the vaccine in preventing severe RSV-associated respiratory infections. At this point, use ...
近日,美国食品药品监督管理局(FDA)已批准辉瑞公司的呼吸道合胞病毒(RSV)疫苗Abrysvo(RSVpreF),用于预防18至59岁因RSV引起的下呼吸道疾病(LRTD)风险较高的人群。 2023年5月底,FDA首次批准RSV疫苗Abrysvo上市,用于预防60岁及以上成人由RSV引起的急性呼吸道疾病和下呼吸道疾病。同年8月,FDA再度批准该疫苗用于通过对...